{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:53:12Z","timestamp":1791067992671,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"DOI":"10.1007\/s40487-026-00465-4","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:05:41Z","timestamp":1791021941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World First-Line Treatment Characteristics and Physician Drivers in Advanced\/Metastatic Non\u2013Small Cell Lung Cancer, PD-L1 \u2265 50%, and without Actionable Genomic Alterations"],"prefix":"10.1007","author":[{"given":"Dwight H.","family":"Owen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani K.","family":"Mhatre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderjit K.","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmina","family":"Hogea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Forshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delvys","family":"Rodr\u00edguez-Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"465_CR1","unstructured":"American Cancer Society. Cancer Facts & Figures [Internet]. 2025. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2025\/2025-cancer-facts-and-figures-acs.pdf. Accessed 20 May, 2026."},{"issue":"10","key":"465_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):937\u201370. https:\/\/doi.org\/10.1002\/cac2.12359.","journal-title":"Cancer Commun (Lond)"},{"issue":"12","key":"465_CR3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824\u201332. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4932.","journal-title":"JAMA Oncol"},{"issue":"1","key":"465_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10(1):71. https:\/\/doi.org\/10.1038\/s41572-024-00551-9.","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 4","key":"465_CR5","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192\u2013237. https:\/\/doi.org\/10.1093\/annonc\/mdy275.","journal-title":"Ann Oncol"},{"issue":"14","key":"465_CR6","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1200\/JCO.19.03022","volume":"38","author":"NH Hanna","year":"2020","unstructured":"Hanna NH, Schneider BJ, Temin S, et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2020;38(14):1608\u201332. https:\/\/doi.org\/10.1200\/JCO.19.03022.","journal-title":"J Clin Oncol"},{"issue":"9","key":"465_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1704795.","journal-title":"N Engl J Med"},{"issue":"2","key":"465_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"issue":"15","key":"465_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154476","volume":"13","author":"I Attili","year":"2024","unstructured":"Attili I, Asnaghi R, Vacirca D, et al. Co-occurring driver genomic alterations in advanced non-small-cell lung cancer (NSCLC): a retrospective analysis. J Clin Med. 2024;13(15):4476. https:\/\/doi.org\/10.3390\/jcm13154476.","journal-title":"J Clin Med"},{"issue":"3","key":"465_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14031025","volume":"14","author":"K Tahayneh","year":"2025","unstructured":"Tahayneh K, Idkedek M, Abu Akar F. NSCLC: current evidence on its pathogenesis, integrated treatment, and future perspectives. J Clin Med. 2025;14(3):1025. https:\/\/doi.org\/10.3390\/jcm14031025.","journal-title":"J Clin Med"},{"issue":"6","key":"465_CR11","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1007\/s12094-023-03362-8","volume":"26","author":"M Provencio-Pulla","year":"2024","unstructured":"Provencio-Pulla M, Perez-Parente D, Olson S, et al. Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer. Clin Transl Oncol. 2024;26(6):1384\u201394. https:\/\/doi.org\/10.1007\/s12094-023-03362-8.","journal-title":"Clin Transl Oncol"},{"key":"465_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1615795","volume":"15","author":"D Nayak","year":"2025","unstructured":"Nayak D, Akers KG, Frederickson AM, Mbous YPV, Aguiar-Ibanez R. Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy. Front Oncol. 2025;15:1615795. https:\/\/doi.org\/10.3389\/fonc.2025.1615795.","journal-title":"Front Oncol"},{"issue":"1","key":"465_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-80301-9","volume":"15","author":"P Ngo","year":"2025","unstructured":"Ngo P, Cooper WA, Wade S, et al. Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis. Sci Rep. 2025;15(1):4166. https:\/\/doi.org\/10.1038\/s41598-024-80301-9.","journal-title":"Sci Rep"},{"issue":"24","key":"465_CR14","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1200\/JCO-25-01062","volume":"43","author":"DH Owen","year":"2025","unstructured":"Owen DH, Halmos B, Puri S, et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2025.1. J Clin Oncol. 2025;43(24):e45\u201358. https:\/\/doi.org\/10.1200\/JCO-25-01062.","journal-title":"J Clin Oncol"},{"issue":"28","key":"465_CR15","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.22.00825","volume":"40","author":"N Singh","year":"2022","unstructured":"Singh N, Temin S, Baker S Jr, et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline. J Clin Oncol. 2022;40(28):3323\u201343. https:\/\/doi.org\/10.1200\/JCO.22.00825.","journal-title":"J Clin Oncol"},{"issue":"1","key":"465_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/ajco.14205","volume":"22","author":"J Cheng","year":"2026","unstructured":"Cheng J, McKay C, Bray V, Yip PY, Tognela A, Kok PS. Real-world survival outcomes of patients with high PD-L1 advanced NSCLC who received chemoimmunotherapy versus immunotherapy. Asia Pac J Clin Oncol. 2026;22(1):149\u201356. https:\/\/doi.org\/10.1111\/ajco.14205.","journal-title":"Asia Pac J Clin Oncol"},{"key":"465_CR17","doi-asserted-by":"publisher","unstructured":"Akinboro O, Vallejo JJ, Nakajima EC, et al. Outcomes of anti\u2013PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non\u2013small cell lung cancer (NSCLC) with PD-L1 score. J Clin Oncol. 2022;40(16_suppl):9000. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9000.","DOI":"10.1200\/JCO.2022.40.16_suppl.9000"},{"issue":"10","key":"465_CR18","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares L, Vicente D, Tafreshi A, et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol. 2020;15(10):1657\u201369. https:\/\/doi.org\/10.1016\/j.jtho.2020.06.015.","journal-title":"J Thorac Oncol"},{"issue":"14","key":"465_CR19","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505\u201317. https:\/\/doi.org\/10.1200\/JCO.19.03136.","journal-title":"J Clin Oncol"},{"issue":"21","key":"465_CR20","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1810865.","journal-title":"N Engl J Med"},{"issue":"2","key":"465_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024;42(2):209-24 e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.013.","journal-title":"Cancer Cell"},{"key":"465_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383456","volume":"15","author":"SA Javed","year":"2024","unstructured":"Javed SA, Najmi A, Ahsan W, Zoghebi K. Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges. Front Immunol. 2024;15:1383456. https:\/\/doi.org\/10.3389\/fimmu.2024.1383456.","journal-title":"Front Immunol"},{"issue":"11","key":"465_CR23","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372. https:\/\/doi.org\/10.1185\/03007990802457040.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"465_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352. https:\/\/doi.org\/10.1136\/bmjopen-2015-010352.","journal-title":"BMJ Open"},{"key":"465_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2000","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2000;9:371\u201380. https:\/\/doi.org\/10.2147\/DMSO.S120101.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"465_CR26","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;39(12):1707\u201315. https:\/\/doi.org\/10.1080\/03007995.2023.2279679.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"465_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"465_CR28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","volume":"22","author":"AS Pickard","year":"2019","unstructured":"Pickard AS, Law EH, Jiang R, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931\u201341. https:\/\/doi.org\/10.1016\/j.jval.2019.02.009.","journal-title":"Value Health"},{"issue":"10","key":"465_CR29","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res"},{"issue":"5","key":"465_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087.","journal-title":"Ann Med"},{"issue":"5","key":"465_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"key":"465_CR32","unstructured":"European Pharmaceutical Market Research Association. Code of Conduct [Internet]. 2024. https:\/\/www.ephmra.org\/sites\/default\/files\/2024-09\/2024%20EPHMRA%20Code%20of%20Conduct%20Final.pdf. Accessed 20 May, 2026."},{"key":"465_CR33","unstructured":"World Medical Association. WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Participants [Internet]. 2025. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki. Accessed 20 May, 2026."},{"key":"465_CR34","unstructured":"United States Department of Health and Human Services. Summary of the HIPAA Privacy Rule [Internet]. 2003. http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf. Accessed 20 May, 2026."},{"key":"465_CR35","unstructured":"Health Information Technology (HITECH). Health Information Technology Act [Internet]. 2009. https:\/\/healthit.gov\/wp-content\/uploads\/2025\/06\/hitech_act_excerpt_from_arra_with_index.pdf. Accessed 20 May, 2026."},{"key":"465_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611713","volume":"30","author":"A Lieber","year":"2024","unstructured":"Lieber A, Makai A, Orosz Z, et al. The role of immunotherapy in early-stage and metastatic NSCLC. Pathol Oncol Res. 2024;30:1611713. https:\/\/doi.org\/10.3389\/pore.2024.1611713.","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"465_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.59380","volume":"8","author":"VS Ahluwalia","year":"2025","unstructured":"Ahluwalia VS, Parikh RB. Chemoimmunotherapy vs immunotherapy monotherapy receipt in advanced non-small cell lung cancer. JAMA Netw Open. 2025;8(2):e2459380. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.59380.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"465_CR38","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41591-024-02929-4","volume":"30","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Hu CH, Li YZ, et al. Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer. Nat Med. 2024;30(6):1680\u20138. https:\/\/doi.org\/10.1038\/s41591-024-02929-4.","journal-title":"Nat Med"},{"issue":"1","key":"465_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00520-013-1959-4","volume":"22","author":"S Iyer","year":"2014","unstructured":"Iyer S, Roughley A, Rider A, Taylor-Stokes G. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Support Care Cancer. 2014;22(1):181\u20137. https:\/\/doi.org\/10.1007\/s00520-013-1959-4.","journal-title":"Support Care Cancer"},{"issue":"2","key":"465_CR40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.lungcan.2013.03.008","volume":"81","author":"S Iyer","year":"2013","unstructured":"Iyer S, Taylor-Stokes G, Roughley A. Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany. Lung Cancer. 2013;81(2):288\u201393. https:\/\/doi.org\/10.1016\/j.lungcan.2013.03.008.","journal-title":"Lung Cancer"},{"issue":"2","key":"465_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00520-023-07590-0","volume":"31","author":"L Ma","year":"2023","unstructured":"Ma L, Zhu K, Shi C, et al. Association between the patients\u2019 symptom burden and their family caregivers\u2019 benefit finding in non-small cell lung cancer receiving combined chemotherapy. Support Care Cancer. 2023;31(2):148. https:\/\/doi.org\/10.1007\/s00520-023-07590-0.","journal-title":"Support Care Cancer"},{"issue":"1","key":"465_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40117-5","volume":"13","author":"SM Lin","year":"2023","unstructured":"Lin SM, Yang SC, Wu TI, Wang JD, Liu LF. Estimation of disability free life expectancy in non small cell lung cancer based on real world data. Sci Rep. 2023;13(1):13318. https:\/\/doi.org\/10.1038\/s41598-023-40117-5.","journal-title":"Sci Rep"},{"issue":"3","key":"465_CR43","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s11764-021-01024-8","volume":"15","author":"J Lai-Kwon","year":"2021","unstructured":"Lai-Kwon J, Heynemann S, Flore J, et al. Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. J Cancer Surviv. 2021;15(3):392\u20137. https:\/\/doi.org\/10.1007\/s11764-021-01024-8.","journal-title":"J Cancer Surviv"},{"key":"465_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","volume":"107","author":"S Nolte","year":"2019","unstructured":"Nolte S, Liegl G, Petersen MA, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the United States. Eur J Cancer. 2019;107:153\u201363. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.024.","journal-title":"Eur J Cancer"},{"issue":"1","key":"465_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000158","volume":"3","author":"K Liao","year":"2024","unstructured":"Liao K, Wong DC, Gomes F, et al. Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapy. BMJ Oncol. 2024;3(1):e000158. https:\/\/doi.org\/10.1136\/bmjonc-2023-000158.","journal-title":"BMJ Oncol"},{"issue":"11","key":"465_CR46","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","volume":"36","author":"A Zer","year":"2025","unstructured":"Zer A, Ahn MJ, Barlesi F, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(11):1245\u201362. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.003.","journal-title":"Ann Oncol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00465-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00465-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00465-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:02:08Z","timestamp":1791064928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00465-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":46,"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00465-4","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Martin Sebastian: research funding: Gilead; grants or contracts: AstraZeneca, Gilead; payment or honoria: AstraZeneca, Sanofi, Merck; support for attending meetings\/travel: Pfizer, Takeda, Merck; participation on a DSMB or advisory board: Amgen, Novartis, Boehringer-Ingelheim, Pfizer, AstraZeneca, Takeda, Pierre-Fabre, Gilead, Daiichi Sankyo Co., Ltd., Sanofi, Regeneron; Dwight H. Owen: research funding to institution: BMS, Merck, Palobiofarma, Genentech, Pfizer, Onc.AI. Honorarium: Chugai; Hirotsugu Kenmotsu: Ono Pharmaceuticals Co, Novartis Pharma K.K., AstraZeneca K.K., Loxo Oncology; speakers bureau: Amgen, Inc., AstraZeneca K.K., Bayer, Boehringer- Ingelheim, BMS, Chugai Pharm. Co Ltd., Daichi Sankyo Co., Ltd., Eli Lilly K.K., Kyoto Hakko Kirin Co., Ltd., Merck, MSD, Novartis Pharma K.K., Ono Pharmaceutical Co, Ltd., Pfizer, Taiho Pharma, Takeda Pharma, Co Ltd.; Shilpa Viswanathan, Shivani K. Mhatre, Cosmina Hogea, Inderjit K. Dhillon: employment and stockholder at Gilead; Cameron Forshaw, Hollie Bailey: employment at Adelphi; Delvys Rodr\u00edguez-Abreu: advisory board and invited speaker: MSD, Roche\/Genentech, Novartis, Pfizer, BMS, AstraZeneca, Regeneron, Gilead, Sanofi, Amgen, Eli Lilly, Merck Serono; advisory board: Incyte; support for travel: MSD, Novartis, Roche\/Genentech, Pfizer. Siwen Ding is employed by and shareholder of Gilead Sciences Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Adelphi Real-World NSCLC DSP was conducted in line with EphMRA guidelines [\n                      \n                      ] and survey materials were submitted to the PEARL IRB (ID: 2023-0318) and were deemed to be exempt. Each survey was performed in full accordance with the Declaration of Helsinki of 1964 (and its later amendments) [\n                      \n                      ], the United States Health Insurance Portability and Accountability Act 1996 [\n                      \n                      ], and Health Information Technology for Economic and Clinical Health Act legislation [\n                      \n                      ]. All participants provided their informed consent to take part in the self-report questionnaire, and no identifiable protected health information was extracted during the course of the survey. Data were anonymized and aggregated before being shared with the study team and\/or for analysis and publication.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}